CD2-targeted nanoparticles encapsulating IL-2 induce tolerogenic Tregs and TGF-beta-producing NK cells that stabilize Tregs for long-term therapeutic efficacy in immune-mediated disorders
Related Posts
Sergeev I, Prchal JT, Nouraie SM, Shah BN, Zhang X, Sergueeva A, Miasnikova G, Ganz T, Gordeuk VR. VHL, transferrin, and erythropoietin in the regulation[...]
Johnsen NA, Carlisle R, Baghoomian W, Pierce JL, Nguyen MO. A novel case of acute localized and generalized exanthematous pustulosis following IL-2 analogue injection amplified[...]
Yan MJ, Shen A, Galamgam J, Hogeling M, Cheng C. A rare case of dystrophic calcinosis cutis in an infant. JAAD Case Rep. 2025 Oct[...]